Bictegravir/emtricitabine/tenofovir alafenamide in clinical practice for people with HIV: final 24-month effectiveness and safety outcomes in key populations in the observational BICSTaR cohort

CONCLUSIONS: B/F/TAF was generally well tolerated over 24 months, with high effectiveness and persistence observed among a broad range of people with …